Navigation Links
Bayer Announces Farnam Companies' Agreement to Halt Disputed Bio Spot® Ads
Date:6/17/2011

SHAWNEE, Kan., June 17, 2011 /PRNewswire/ -- Bayer HealthCare LLC announced today that it has reached a successful resolution of the lawsuit between Bayer and Farnam Companies Inc. over Farnam's advertising for its Bio Spot® flea and tick control products.  As part of the settlement, Farnam has agreed to withdraw the challenged advertising.

Farnam's print and online advertising campaign included claims that Bio Spot® was "as effective as popular vet brands," that Bio Spot® was "the best flea and tick control available," and that Bio Spot® was "the choice of professionals."  Farnam did not have any head-to-head clinical studies supporting its claims that its products were superior to, or as effective as, Bayer's premium flea and/or tick control products Advantage® II and K9 Advantix® II.  Bayer argued in a challenge submitted to the National Advertising Division of the Council of Better Business Bureaus (or NAD) that Farnam's advertising claims were false and unsubstantiated; Farnam responded by filing a lawsuit in the United States District Court for the District of Arizona seeking a declaration that its advertising was not false.

Today's settlement announcement ends both the NAD challenge and federal lawsuit.  As part of the settlement, Farnam has agreed to discontinue all of the advertising claims challenged by Bayer, and will refrain from making similar unsupported claims in future advertising.  Farnam will be given a short transition period to make the necessary changes to all of its advertising materials.

Bayer was represented by David H. Bernstein and Christopher Hamilton of Debevoise & Plimpton LLP, and Nicole Goodwin of Quarles & Brady LLP.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR
'/>"/>

SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Bayers Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
2. Bayers Discrimination Lawsuit Now Requires Extra-Strength Cure
3. Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Bayer HealthCare to Sponsor World Federation of Hemophilia Global Training Program and Donate Kogenate® FS, Antihemophilic Factor (Recombinant), Commercially Valued At More Than $7 Million
5. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
6. Two New Studies in the British Medical Journal Find That Bayers Yaz and Yasmin Birth Control Pills Have an Increased Risk of Blood Clot
7. Bayer Launches First Interactive Virtual Walk in Support of Hemophilia
8. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
9. Bayer HealthCare Selects the State of New Jersey for East Coast Site Consolidation
10. Bayer Gets $100M Gender Class Action Headache
11. TV Personality Vanessa Minnillo Teams Up With Bayer and March of Dimes to Launch National Folate Awareness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... -,Phytopharm plc (LSE: PYM) ("Phytopharm" or the ... reverses the,changes in the area of the ... be presented by Dr Jonathan Brotchie, an,internationally ... International Congress of Parkinson's Disease and Movement,Disorders' ...
... UVIDEM was well-tolerated with signs of durable,disease control ... 05, 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. today presented ... vaccine clinical trial (DC-MEL-202). The,results showed that UVIDEM ... of immune response in patients with,progressive metastatic melanoma. ...
Cached Medicine Technology:Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 2Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 3Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 4Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 5IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5
(Date:4/20/2014)... its potentially harmful effects in children, codeine continues to ... research from UCSF Benioff Children,s Hospital San Francisco. , ... , solutions include changing provider prescription behaviors to promote ... ibuprofen or hydrocodone. , "Despite strong evidence against the ... be prescribed to large numbers of them each year," ...
(Date:4/18/2014)... 2014) -- A group of scientists from the ... Sanders-Brown Center on Aging has found interesting new ... function in Parkinson,s disease (PD). , Published ... study, which assessed cognitive function in depressed and ... replacement therapy commonly used to treat motor symptoms ...
(Date:4/18/2014)... have made a discovery that turns 160 years of ... material long known to be essential for the fast ... is not as ubiquitous as thought, according to a ... Harvard Stem Cell Institute (HSCI) and the University,s Department ... Professor Jeff Lichtman, of Harvard,s Department of Molecular and ...
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
Breaking Medicine News(10 mins):Health News:UCSF study finds codeine often prescribed to children, despite available alternatives 2Health News:Treating depression in PD patients: New research 2Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3
... Confirms Part D Seniors Also Enjoy Broad Choice of,Prescription ... Association (PCMA) issued the following statement on new budget,figures ... is lower over the,next ten years than was estimated ... without sacrificing beneficiaries,choice of prescription drugs. New budget documents ...
... Nursing Home Care to Face,Severe Resistance, JOPLIN, Mo., ... today reporting the Bush Administration plans to cut,U.S. seniors, ... to,be unveiled Monday, the Coalition to Protect Senior Care ... as it did last summer and fall when the,Coalition ...
... Mettler-Toledo,International Inc. (NYSE: MTD ) today announced ... fourth-quarter results on Thursday, February,7, 2008 at 5:00 p.m. ... call,visit http://www.mt.com/investors on the Company,s website. A ... 2008., METTLER TOLEDO is a leading global supplier ...
... off Sponsorship of Living ... Aid Retired NFL Players, PHOENIX, Jan. 31 Retired ... are more than twice as likely,as the general population to ... stroke and other cardiovascular (CV) diseases, according to,a recent study ...
... Ill., Jan. 31 Horace Mann,Educators Corporation (NYSE: ... Wednesday, February 6, 2008 after the market closes. The,earnings ... Relations section of the Company,s website at http://www.horacemann.com ... financial results on,Thursday, February 7, 2008 at 10:00 a.m. ...
... 31 National opinion leaders will,convene in Arlington, ... data,guidelines, practical applications, and strategies for the treatment ... make the,meeting highly interactive., The Summit will ... sponsored,by The Dannemiller Educational Foundation, and the content ...
Cached Medicine News:Health News:Coalition to Protect Senior Care Gearing Up to Fight Bush Administration Medicare Cuts 2Health News:NFL Linemen Predisposed to Cardiovascular Disease; Early Detection is Key to Getting and Staying Healthy 2Health News:NFL Linemen Predisposed to Cardiovascular Disease; Early Detection is Key to Getting and Staying Healthy 3Health News:Horace Mann Announces Fourth Quarter Earnings Release and Conference Call 2Health News:Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery 2Health News:Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: